NovaBridge Biosciences (NBP) Liabilities and Shareholders Equity (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $260.5 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 22.49% year-over-year to $260.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $953.6 million (up 36.38% YoY) and the FY2025 annual result came in at $260.5 million, up 22.49% from the prior year.
• Liabilities and Shareholders Equity retreated to $260.5 million in Q4 2025 per NBP's latest filing, from $277.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $952.2 million in Q2 2021 and bottomed at $206.7 million in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $277.4 million (2025), against an average of $436.5 million.
• The widest annual swing landed in 2021, when Liabilities and Shareholders Equity soared 229.32%; it then sank 49.37% in 2024.
• Tracing NBP's Liabilities and Shareholders Equity over 5 years: stood at $876.1 million in 2021, then sank by 34.62% to $572.8 million in 2022, then tumbled by 36.64% to $362.9 million in 2023, then plunged by 41.4% to $212.7 million in 2024, then rose by 22.49% to $260.5 million in 2025.
• Per Business Quant, the three latest NBP Liabilities and Shareholders Equity figures stand at $260.5 million (Q4 2025), $277.4 million (Q3 2025), and $206.7 million (Q2 2025).

Peer Comparison